2 terminated, 1 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Withdrawn 1 |
Follow figitumumab: new trials by email Literature Review of figitumumab trials Research Report on figitumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer CP-751,871, Cisplatin, Gemcitabine - Carcinoma, Non-Small-Cell Lung | Phase 3 | Withdrawn | Pfizer | 2010-07-01 | 2014-06-17 | |
| Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer CP 751,871 (Figitumumab), Erlotinib - Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Pfizer | 583 | 2008-05-01 | 2013-07-24 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology CP-751,871 (Figitumumab), Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Carcinoma, Adenosquamous | Phase 3 | Terminated | Pfizer | 681 | 2008-04-01 | 2014-01-13 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Large Cell (2) · Carcinoma, Squamous Cell (2) · Carcinoma (1) · Carcinoma, Adenosquamous (1)
Pfizer (3)
Brazil (2) · Bulgaria (2) · Canada (2) · Czechia (2) · France (2) · Greece (2) · Hungary (2) · Italy (2) · Poland (2) · Puerto Rico (2) · Russia (2) · South Korea (2) · Spain (2) · Switzerland (2) · Taiwan (2)